Apollomics Inc.
Apollomics Inc. (APLM): 3 pipeline candidates · ~1 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.0 months
0% dilution
Lead: Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for Apollomics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$31.8M
Cash
$9.8M
Quarterly Burn
$28.7M
Runway
1.0 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| apl-101 | Phase 2 |
| apl-102 | Phase 2 |
| uproleselan | Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$7K
| Holder | Shares | Value |
|---|---|---|
| citigroup inc | 438 | $7K |
| blackrock, inc. | 1 | $16 |
Frequently asked questions
How many drug candidates are in Apollomics Inc.'s pipeline?
Apollomics Inc. (APLM) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Apollomics Inc.'s lead drug candidate?
Apollomics Inc.'s most advanced tracked candidate is apl-101 (Phase 2) for Solid Tumors.
What is Apollomics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Apollomics Inc. has approximately 1.0 months of cash runway.
What is Apollomics Inc.'s market capitalization?
Apollomics Inc.'s market capitalization is approximately $31.8M.
Who is the CEO of Apollomics Inc.?
Mr. Hung-Wen Chen is the chief executive officer of Apollomics Inc. (APLM).
Get the full picture on Apollomics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.